Poluzzi E - Search Results

1

Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

Fusaroli M, Isgrò V, Cutroneo PM, Ferrajolo C, Cirillo V, Del Bufalo F, Raschi E, Poluzzi E, Trifirò G. Fusaroli M, et al. Among authors: poluzzi e. Drug Saf. 2022 Aug;45(8):891-908. doi: 10.1007/s40264-022-01194-z. Epub 2022 Jul 12. Drug Saf. 2022. PMID: 35829913 Free PMC article.

2

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. De Ponti F, et al. Among authors: poluzzi e. Drug Saf. 2002;25(4):263-86. doi: 10.2165/00002018-200225040-00004. Drug Saf. 2002. PMID: 11994029 Review.

3

The hERG K+ channel: target and antitarget strategies in drug development.

Raschi E, Vasina V, Poluzzi E, De Ponti F. Raschi E, et al. Among authors: poluzzi e. Pharmacol Res. 2008 Mar;57(3):181-95. doi: 10.1016/j.phrs.2008.01.009. Epub 2008 Feb 2. Pharmacol Res. 2008. PMID: 18329284 Review.

4

Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H, De Ponti F. Raschi E, et al. Among authors: poluzzi e. Br J Clin Pharmacol. 2009 Jan;67(1):88-98. doi: 10.1111/j.1365-2125.2008.03319.x. Epub 2008 Nov 17. Br J Clin Pharmacol. 2009. PMID: 19076158 Free PMC article. Review.

5

Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

Poluzzi E, Raschi E, Moretti U, De Ponti F. Poluzzi E, et al. Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):512-8. doi: 10.1002/pds.1746. Pharmacoepidemiol Drug Saf. 2009. PMID: 19358226

6

Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.

Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Poluzzi E, et al. Drug Saf. 2010 Apr 1;33(4):303-14. doi: 10.2165/11531850-000000000-00000. Drug Saf. 2010. PMID: 20297862

7

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting.

Piccinni C, Motola D, Marchesini G, Poluzzi E. Piccinni C, et al. Among authors: poluzzi e. Diabetes Care. 2011 Jun;34(6):1369-71. doi: 10.2337/dc10-2412. Epub 2011 Apr 22. Diabetes Care. 2011. PMID: 21515844 Free PMC article.

8

QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus.

Raschi E, Poluzzi E, Koci A, Boriani G, De Ponti F. Raschi E, et al. Among authors: poluzzi e. Br J Clin Pharmacol. 2011 Nov;72(5):839-41. doi: 10.1111/j.1365-2125.2011.04065.x. Br J Clin Pharmacol. 2011. PMID: 21777270 Free PMC article. No abstract available.

9

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.

Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. Raschi E, et al. Among authors: poluzzi e. Acta Diabetol. 2013 Aug;50(4):569-77. doi: 10.1007/s00592-011-0340-7. Epub 2011 Oct 19. Acta Diabetol. 2013. PMID: 22008948

10

Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.

Motola D, Piccinni C, Biagi C, Raschi E, Marra A, Marchesini G, Poluzzi E. Motola D, et al. Among authors: poluzzi e. Drug Saf. 2012 Apr 1;35(4):315-23. doi: 10.2165/11596510-000000000-00000. Drug Saf. 2012. PMID: 22376166

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters